Healing Chemistry with a Hidden Contaminant: PFAS in Pharma Manufacturing
The pharmaceutical industry—dedicated to developing medicines that improve and extend human life—ironically relies on PFAS compounds throughout its manufacturing processes. From the fluoropolymer-lined reactors where active pharmaceutical ingredients (APIs) are synthesized, to the fluorinated solvents used in drug purification, to the PFAS-containing excipients in some formulations, PFAS is deeply embedded in pharmaceutical chemistry. As the industry increasingly confronts PFAS contamination from its manufacturing sites and supply chains, pharmaceutical companies face regulatory and reputational pressures that are driving a sector-wide assessment of PFAS dependencies.
PFAS in API Synthesis
Many active pharmaceutical ingredients contain fluorine atoms as part of their molecular structure—fluorinated drugs represent approximately 20% of all FDA-approved pharmaceuticals, including blockbuster medications like fluoxetine (Prozac), ciprofloxacin, atorvastatin (Lipitor), and numerous oncology drugs. While these fluorinated APIs are not technically PFAS in the regulatory sense (they lack the perfluoroalkyl chain characteristic of PFAS), their synthesis often uses PFAS-related fluorinating reagents and fluoropolymer process equipment that introduces PFAS contamination into manufacturing environments and wastewater.
Perfluorinated solvent systems—particularly perfluorooctyl bromide and related compounds—are used in pharmaceutical research as oxygen carriers in artificial blood and as MRI contrast agents. Perfluorocarbon-based drug delivery systems have been investigated for inhaled drug administration and targeted delivery applications. These applications exist in a regulatory gray zone: they involve PFAS-like compounds used intentionally for therapeutic purposes, requiring individual FDA safety assessments distinct from environmental PFAS restrictions.
Manufacturing Facility PFAS Discharges
Pharmaceutical manufacturing facilities—both in the United States and in major API production hubs in India and China—discharge process wastewater containing PFAS from manufacturing operations. Studies of waterways near pharmaceutical manufacturing clusters in Hyderabad, India and along the Yangtze River delta in China have documented elevated PFAS concentrations associated with pharmaceutical industry discharges. In the United States, several pharmaceutical companies have been identified as significant contributors to PFAS loading in waterways near their manufacturing facilities.
The expected EPA effluent guidelines for pharmaceutical manufacturing will likely address PFAS discharges explicitly, requiring pharmaceutical facilities to characterize and control PFAS discharges through pretreatment or internal treatment systems. European pharmaceutical manufacturers face similar pressures under the EU’s Industrial Emissions Directive and the emerging PFAS restriction proposal, which may require PFAS phase-out from manufacturing processes where alternatives are technically feasible.
Supply Chain Transparency and Green Chemistry Initiatives
Leading pharmaceutical companies including GSK, AstraZeneca, Pfizer, and Novartis are participating in green chemistry initiatives that specifically address PFAS use in manufacturing processes. The ACS Green Chemistry Institute’s Pharmaceutical Roundtable has identified fluorinated solvent replacement as a priority research area, developing solvent selection guides that highlight PFAS concerns alongside traditional environmental, health, and safety metrics. Pharmaceutical supply chain auditing is increasingly including PFAS use disclosure requirements for contract manufacturing organizations (CMOs), bringing visibility to a previously opaque aspect of pharmaceutical PFAS exposure.